Insomnia - Pipeline Review, H2 2011
Global Markets Direct’s, 'Insomnia - Pipeline Review, H2 2011', provides an overview of the Insomnia therapeutic pipeline. This report provides information on the therapeutic development for Insomnia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Insomnia. 'Insomnia - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Insomnia.
- A review of the Insomnia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Insomnia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Insomnia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effe
Insomnia – Pipeline Review, H2 2011 Insomnia - Pipeline Review, H2 2011 Reference Code: GMDHC1343IDB Publication Date: September 2011 Insomnia – Pipeline Review, H2 2011 GMDHC1343IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Insomnia – Pipeline Review, H2 2011 Ta b le o f Co n te n ts Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Insomnia Overview 9 Therapeutics Development 10 An Overview of Pipeline Products for Insomnia 10 Insomnia Therapeutics under Development by Companies 12 Insomnia Therapeutics under Investigation by Universities/Institutes 14 Late Stage Products 15 Comparative Analysis 15 Mid Clinical Stage Products 16 Comparative Analysis 16 Early Clinical Stage Products 17 Comparative Analysis 17 Discovery and Pre-Clinical Stage Products 18 Comparative Analysis 18 Insomnia Therapeutics - Products under Development by Companies 19 Insomnia Therapeutics - Products under Investigation by Universities/Institutes 21 Companies Involved in Insomnia Therapeutics Development 22 Eli Lilly and Company 22 GlaxoSmithKline plc 22 Merck & Co., Inc. 23 Dainippon Sumitomo Pharma Co., Ltd. 23 Takeda Pharmaceutical Company Limited 24 Alexza Pharmaceuticals, Inc. 24 Eisai Co., Ltd. 25 Evotec Aktiengesellschaft 25 IntelGenx Technologies Corp. 26 Arena Pharmaceuticals, Inc. 26 Jazz Pharmaceuticals, Inc. 27 Transcept Pharmaceuticals, Inc. 27 Neurim Pharmaceuticals (1991) Ltd. 28 Abeille Pharmaceuticals, Inc. 28 Intec Pharma ltd. 29 Ferrer Internacional S.A. 29 Rottapharm SpA 30 Somnus Therapeutics, Inc. 30 Intra-Cellular Therapies, Inc. 31 Heptares Therapeutics Ltd. 31 Eurofarma 32 Insomnia - Therapeutics Assessment 33 Assessment by Monotherapy Products 33 Assessment by Combination Products 34 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Insomnia – Pipeline Review, H2 2011 GMDHC1343IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2) Insomnia – Pipeline Review, H2 2011 Drug Profiles 39 JZP-6 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 LY2624803 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 MK-4305 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 AZ-007 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 SEP-0227018 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 SB-649868 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Neu-P11 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Intermezzo - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 AB-1003 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 SKP-1041 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Orexin 2 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 ITI-007 - Drug Profile 53 Product Description 53 Mechanism of Action 53 Insomnia – Pipeline Review, H2 2011 GMDHC1343IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3) Insomnia – Pipeline Review, H2 2011 R&D Progress 53 CR 5542 Series - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Vestipitant - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 GF-015535-00 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Melatonin - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Escitalopram + Sertraline + Desvenlafaxine - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Eszopiclone - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Lunesta + Venlafaxine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Armodafinil - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Ramelteon + Doxepin - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Rozerem + Gabapentin - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 APD125 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Melatonin - Drug Profile 66 Product Description 66 Mechanism of Action 66 Insomnia – Pipeline Review, H2 2011 GMDHC1343IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(4) Insomnia – Pipeline Review, H2 2011 R&D Progress 66 Trazodone - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 MK-6096 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Lunesta - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Zaleplon GR - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 MK-3697 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 SEP-190 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 INT0020 - Drug Profile
Pages to are hidden for
"Insomnia Pipeline Review H2 2011"Please download to view full document